Shares of healthcare data analytics company Health Catalyst (NASDAQ:HCAT) fell 4.2% in the afternoon session after Wells Fargo downgraded the company's stock to Equal Weight from Overweight and significantly cut its price target.

The firm lowered its price target to $1.00 from $5.00, citing concerns about structural issues that may continue even after the company's replatforming efforts. The bank noted that Health Catalyst had missed expectations for both client retention and growth. This action followed the company's recent financial report for the fourth quarter of 2025, which presented mixed results. While revenue surpassed expectations, earnings per share of $0.08 fell short of forecasts. Furthermore, the company provided a weak revenue outlook for the first quarter of 2026, projecting a decline.

The shares closed the day at $1.16, down 1.3% from previous close.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Health Catalyst? Access our full analysis report here, it’s free.

Health Catalyst’s shares are extremely volatile and have had 48 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 14 days ago when the stock gained 12.4% on the news that a broad rally continued to suggest renewed investor interest in the sector. The move was part of a wider trend that saw the broader software ETF (IGV) outperform the NASDAQ by 9% in the preceding week. This rally followed a period where software stocks had lagged the market. According to analysis from Morgan Stanley, investors were shifting their focus from general artificial intelligence excitement to software companies that provided practical and secure solutions for businesses. The firm noted that enterprise AI adoption was concentrated in targeted uses like software development and information retrieval, signaling a more mature phase of investment in the space.

Health Catalyst is down 49.3% since the beginning of the year, and at $1.16 per share, it is trading 74.9% below its 52-week high of $4.60 from March 2025. Investors who bought $1,000 worth of Health Catalyst’s shares 5 years ago would now be looking at only $24.77.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.